Drug intelligence / Profile preview

NP-G2-044 + pegylated liposomal doxorubicin

Development stage: Unknown
Lead developer: Novita Pharmaceuticals
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

NP-G2-044 + pegylated liposomal doxorubicin is a combination investigational regimen composed of NP-G2-044, a small molecule inhibitor of fascin (an actin-bundling protein involved in cell motility and cancer metastasis), and pegylated liposomal doxorubicin, a formulation of the anthracycline chemotherapy doxorubicin encapsulated in pegylated liposomes to enhance tumor delivery and reduce toxicity[4][2][5][1]. NP-G2-044 inhibits fascin activity, disrupting actin cytoskeleton dynamics required for tumor cell migration and invasion. Pegylated liposomal doxorubicin interferes with DNA replication by inhibiting topoisomerase II, exerting cytotoxic effects on proliferating cancer cells. The combination is under clinical development for treatment of advanced solid tumors, including platinum-resistant ovarian carcinoma, triple negative breast cancer, pancreatic ductal adenocarcinoma, and other malignancies[4][1]. NP-G2-044 is developed by Novita Pharmaceuticals.

Other names: PLD

Targets

FSCN1

Beyond the preview

Go deeper on NP-G2-044 + pegylated liposomal doxorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-G2-044 + pegylated liposomal doxorubicin.

Explore the full profile